Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ecenofloxacin SCHEMBL12590150 | 1.00 | DPP4 (0.63) | DPP4CHRM2DRD1LMNAKDM4E | |
| Ecenofloxacin SCHEMBL5415321 | 1.00 | DPP4 (0.63) | DPP4CHRM2DRD1LMNAKDM4E | |
| Ecenofloxacin SCHEMBL8863108 | 1.00 | DPP4 (0.63) | DPP4CHRM2DRD1LMNAKDM4E | |
| Ecenofloxacin SCHEMBL9066847 | 1.00 | DPP4 (0.63) | DPP4CHRM2DRD1LMNAKDM4E | |
| Ecenofloxacin SCHEMBL1345141 | 1.00 | DPP4 (0.63) | DPP4CHRM2DRD1LMNAKDM4E | |
| Ecenofloxacin SCHEMBL7841221 | 1.00 | DPP4 (0.63) | DPP4CHRM2DRD1LMNAKDM4E | |
| Ecenofloxacin SCHEMBL1230672 | 0.99 | DPP4 (0.62) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL16518637 | 0.93 | DPP4 (0.54) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL7849063 | 0.92 | DPP4 (0.62) | DPP4CHRM2DRD1LMNAKDM4E | |
| SCHEMBL9067081 | 0.92 | DPP4 (0.62) | DPP4CHRM2DRD1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | BAYER INNOVATION GMBH (DE) | 2016-02-18 | — | — | US | claimed |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2014-09-25 | — | — | US | claimed |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2007-08-23 | — | — | US | claimed |
| EP-1408034-A1 | Use of Quinoline derivatives as antibacterial agents | Schulz & Schlimbach GbR (DE) | 2004-04-14 | — | — | EP | claimed |
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | BAYER INNOVATION GMBH (DE) | 2016-02-18 | — | — | US | disclosed |
| US-8975275-B2 | Use of chemotherapeutic agents | BAYER INNOVATION GMBH (DE) | 2015-03-10 | — | — | US | disclosed |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | BAYER INNOVATION GMBH (DE) | 2003-03-06 | — | — | US | disclosed |
| US-5527910-A | BACTERICIDES; STAPHYLOCOCCUS, STREPTOCOCCUS INFECTIONS | CHEIL FOODS & CHEMICALS, INC. (KR) | 1996-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | NQO2, BROX, CYP4X1 | DPP4 307/4885CHRM2 3393/4885DRD1 265/4885 |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | TYMP, TP53, MSH2 | DPP4 2790/4885CHRM2 4725/4885DRD1 3984/4885 |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | TYMP, TP53, MSH2 | DPP4 2790/4885CHRM2 4725/4885DRD1 3984/4885 |
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | TYMP, TP53, MSH2 | DPP4 2790/4885CHRM2 4725/4885DRD1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.